Precision dosing in clinical medicine: present and future

References

• World Health Organization. Medication without harm – global patient safety challenge on medication safety. Geneva: World Health Organization; 2017.
   Google Scholar
• Peck RW. Precision medicine is not just genomics: the right dose for every patient. Annu Rev Pharmacol Toxicol. 2018;58:105–122.
   PubMed Web of Science ®Google Scholar
• Masters JC, Wiernik PH. Are we ready to include organ-impaired patients in oncology trials? A clinical pharmacology perspective on recent recommendations. J Clin Pharmacol. 2018;58(6):701–703.
   PubMed Web of Science ®Google Scholar
• Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Australian Prescriber. 2012;35(3):85–88.
   Web of Science ®Google Scholar
• Rossi S, Hurley E, Sutcliffe A. Australian medicines handbook. 19 ed. Adelaide: The Royal Australian College of General Practitioners, the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and the Pharmaceutical Society of Australia; 2018.
   Google Scholar
• Darwich AS, Ogungbenro K, Vinks AA, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101(5):646–656.
   PubMed Web of Science ®Google Scholar
• Forbes HL, Polasek TM. Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017;8(10):319–328.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Lin FPY, Miners JO, et al. Perpetrators of pharmacokinetic drug-drug interactions from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol. 2011;71(5):727–736.
   PubMed Web of Science ®Google Scholar
• Polasek, TM, Ambler K, Scott HS, et al. Targeted pharmacotherapy after somatic cancer mutation screening. F1000Res. 2016;5:1551.
   PubMedGoogle Scholar
• Martin, MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91(4):734–738.
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–467.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, De Boer A, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–673.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134.
   PubMed Web of Science ®Google Scholar
• Brixner D, Biltaji E, Bress A, et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2016;19(3):213–228.
   PubMed Web of Science ®Google Scholar
• Van Der Wouden CH, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2017;101(3):341–358.
   PubMed Web of Science ®Google Scholar
• Tucker GT. Personalized drug dosage – closing the loop. Pharm Res. 2017;34:1539–1543.
   PubMed Web of Science ®Google Scholar
• Tängdén T, Ramos Martín V, Felton TW, et al. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017;43(7):1021–1032.
   PubMed Web of Science ®Google Scholar
• Duong JK, Kroonen MYAM, Kumar SS, et al. A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. Eur J Clin Pharmacol. 2017;73(8):981–990.
   PubMed Web of Science ®Google Scholar
• Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther. 2015;98(3):298–308.
   PubMed Web of Science ®Google Scholar
• Darwich AS, Ogungbenro K, Hatley OJ, et al. Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Transl Cancer Res. 2017;6(S10):S1512–S1529.
   Google Scholar
• Hauser, AS, Chavali S, Masuho I, et al. Pharmacogenomics of GPCR drug targets. Cell. 2017;172:41–59
   PubMed Web of Science ®Google Scholar
• Morgan ET, Dempsey JL, Mimche SM, et al. Physiological regulation of drug metabolism and transport: pregnancy, microbiome, inflammation, infection and fasting. Drug Metab Dispos. 2018;46:503–513.
   PubMed Web of Science ®Google Scholar
• Peck RW. The right dose for every patient: a key step for precision medicine. Nat Rev Drug Discov. 2016;15(3):145–146.
   PubMed Web of Science ®Google Scholar
• Allerheiligen SR. Impact of modeling and simulation: myth or fact? Clin Pharmacol Ther. 2014;96(4):413–415.
   PubMed Web of Science ®Google Scholar
• Milligan PA, Brown MJ, Marchant B, et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther. 2013;93(6):502–514.
   PubMed Web of Science ®Google Scholar
• Rowland A, Van Dyk M, Hopkins AM, et al. Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clin Pharmacol Ther. 2018. doi:10.1002/cpt.1076. [Epub ahead of print]
   Google Scholar
• Marsousi N, Samer CF, Fontana P, et al. Coadministration of ticagrelor and ritonavir: toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach. Clin Pharmacol Ther. 2016;100(3):295–304.
   PubMed Web of Science ®Google Scholar
• Patel N, Wiśniowska B, Jamei M, et al. Real patient and its virtual twin: application of quantitative systems toxicology modelling in the cardiac safety assessment of citalopram. AAPS J. 2017;20(1):6.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Tucker GT, Sorich MJ, et al. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. Br J Clin Pharmacol. 2018;84(3):462–476.
   PubMed Web of Science ®Google Scholar
• Dinh JC, Black BT, Matzuka BJ, et al. Propsective validation of a population pharmacokinetic model derived dosing algorithm of atomoxetine, a CYP2D6 model substrate. Clin Pharmacol Ther. 2018;103(S1):S29–S30.
   Google Scholar
• Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013;53(5):491–504.
   PubMed Web of Science ®Google Scholar